Hope emerges as new pill targets deadly pancreatic cancer
A new daily pill called daraxonrasib has shown promising results in clinical trials for patients with advanced pancreatic cancer, nearly doubling median survival time. The drug targets a specific mutated protein, offering a significant advancement in treatment options for a historically difficult-to-treat disease.
Why it matters
This development represents a major breakthrough in oncology, providing a new, more effective treatment path for one of the deadliest forms of cancer.
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer. “While not curing the cancer, it is a very large step forward,” said Dr. Zev Wainberg, of the University of California, Los Angeles, who helped lead the study.
The article reports on medical research findings published in a peer-reviewed journal without bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in